Chimeric Antigen Receptor T Cell Therapy (CAR-T): Genetically programmed immune cell binds to and destroys cancer cell / Therapy is now available for the majority of indications
19. September 2022 • Knowledge intensive service
19. September 2022 • Knowledge intensive service
“airea – The Airport Region in Central Germany” is one of the top locations for the pharmaceutical and biotech industries in Germany and the world. Featuring capable manufacturers, biologistics specialists, and a broad-based, highly innovative research landscape, airea is distinguished by its ideal conditions for development and collaboration for businesses and investors from these sectors. This will be emphasized at FlyPharma (Leipzig, September 20–21) by the three partners behind airea: MFAG (the parent company of the airports in Leipzig and Dresden), the Saxony Trade & Invest Corporation, and the Saxony-Anhalt Investment and Marketing Corporation.
“The region is distinguished by its excellent production and supplier structures, not to mention its network of professional and technical expertise. This is vital for the industry due to the complexity of products and processes, and underlines the attractiveness of airea to companies and investors. This is what we plan to convey to a broad audience at FlyPharma,” explained Thomas Horn, the Managing Director of the Saxony Trade & Invest Corporation.
airea spans the entire value chain from R&D through production and marketing to logistics and professional services. The modern, highly capable Leipzig/Halle Airport has CEIV pharmaceutical certification, and can handle temperature- and time-critical pharmaceutical shipments such as vaccines 24/7, making it part of the pharmaceutical trade lanes meeting uniform standards worldwide. The airport also offers a dedicated international distribution network for vaccines and medicines covering Europe, Africa, and the Middle East. What’s more, it’s served by more than 70 cargo airlines flying to over 270 destinations worldwide.
Götz Ahmelmann, CEO of MFAG, had this to say: “Handling temperature- and time-critical cargo is already something we do day in, day out. This is an area we intend to expand and reinforce. We hope to raise airea’s international profile at FlyPharma. We expect this will make us better known among investors and give the marketing of our premises a boost.”
In addition to being fully integrated into the trans-European rail and motorway network, the region is characterized by its skilled workforce as well as the high availability of land and its investment potential. There are attractive vacant sites for a variety of industries not just in the direct vicinity of Leipzig/Halle Airport, but also near Halle, Bernburg, Sandersdorf-Brehna and Wermsdorf. The airport region is particularly attractive to pharmaceutical and biotech companies as well as related service providers.
Said Mathias Obieglo, Project Management Coordinator at the Saxony-Anhalt Investment and Marketing Corporation: “The conditions for investment and growth here are ideal for firms in the pharmaceutical and logistics sectors. By setting up shop here, they’ll be in a perfect position to deliver time-critical cargo from the heart of Germany to its destination. Whether global corporations, inventive medium-sized companies, or young startups, businesses particularly appreciate the potential for cross-industry cooperation.”
Chimeric Antigen Receptor T Cell Therapy (CAR-T): Genetically programmed immune cell binds to and destroys cancer cell / Therapy is now available for the majority of indications
The Smart Infrastructure Hub Leipzig will receive a further 1,9 million euros from the cluster funding of the Saxon Ministry of Economic Affairs.
A relatively small metropolis in Germany’s Free State of Saxony – a dynamic hub for the life science industry? What was just a vision 20 years ago has become a reality for the city of Leipzig, which from October 24-26 co-hosted BIO-Europe, Europe’s largest annual biotech partnering event.
The European Commission has approved the Saxon ERDF/JTF program for the funding period 2021 to 2027.